Les peptides natriurétiques en dialyse : de la théorie à la pratique (notice n° 759851)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04441cam a2200337 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250123102003.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Jean, Guillaume |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Les peptides natriurétiques en dialyse : de la théorie à la pratique |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 21 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les concentrations sériques des peptides natriurétiques, essentiellement le B- type natriuretic peptide et le N-terminal pro-Brain natriuretic peptide, sont utilisées en cardiologie et dans les services d’urgence pour le diagnostic de l’insuffisance cardiaque. Leur utilité chez les patients insuffisants rénaux est discutée en raison de leur accumulation et d’une élimination partielle par les séances de dialyse. Chez les patients dialysés, des valeurs élevées de ces peptides sont associées à la mortalité, à l’hypertrophie ventriculaire gauche et à l’insuffisance cardiaque, mais il est difficile de faire un diagnostic sur une valeur isolée. Après avoir défini une valeur de référence de ces peptides au poids sec, leur évolution dépend essentiellement de la volémie, d’une cardiopathie (rythmique, valvulaire ou coronarienne) et du débit de la fistule artério-veineuse. Nous avons l’expérience du dosage mensuel du B-type natriuretic peptide pour les dialysés stables et hebdomadaire pour les patients instables. Le B-type natriuretic peptide a été choisi pour sa demi-vie plus courte, sa moindre dépendance de la fonction rénale et de la dialyse. Nous illustrons notre expérience dans des cas de surcharge hydrosodée, de cardiopathie de novo, d’hypovolémie et d’hyperdébit de fistule artério-veineuse. Le suivi longitudinal du B-type natriuretic peptide constitue un progrès important dans la prise en charge des patients dialysés pour le dépistage et le traitement précoces des variations volémiques et de certaines complications cardiaques qui sont associées au pronostic. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Cardiologists and emergency-wards physicians are used to check natriuretic peptides serum level, mainly B-type natriuretic peptide and N-terminal pro-Brain natriuretic peptide for acute cardiac failure diagnosis. Due to their accumulation in chronic kidney disease and their elimination by dialysis, natriuretic peptides sampling remains debatable in chronic kidney disease patients. In dialysis patients, high natriuretic peptides values are associated with mortality, left ventricular hypertrophy and cardiac failure. However, a single value cannot provide a reliable diagnosis. Our clinical practice is as follows: First, we prefer B-type natriuretic peptide to N-terminal pro-Brain natriuretic peptide because of its shorter half-life, with less impact of renal function and dialysis, making its interpretation easier in case of advanced chronic kidney disease or in dialysis patients; second, we define a reference value of B-type natriuretic peptide at dry weight from serial measurements; third, the B-type natriuretic peptide changes are interpreted according to extracellular fluid and cardiac status, but also from the arteriovenous fistula blood flow. In stable dialysis patients, B-type natriuretic peptide is sampled monthly and weekly in unstable patients. We illustrate our experience using clinical cases of overhydration, new cardiac disease onset, hypovolemia and arteriovenous fistula with high blood flow. Longitudinal follow-up of B-type natriuretic peptide is an important advance in dialysis patients in order to detect and treat extracellular fluid variations and cardiac disease status early, both important factors associated with hard outcomes. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | N-terminal pro-Brain natriuretic peptide |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Fistule artério-veineuse |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Insuffisance cardiaque |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Peptides natriurétiques |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Hémodialyse |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | B-type natriuretic peptide |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | N-terminal pro-Brain natriuretic peptide |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Natriuretic peptides |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Cardiac failure |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Arteriovenous fistulae |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Haemodialysis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | B-type natriuretic peptide |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Deleaval, Patrik |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Chazot, Charles |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Néphrologie & Thérapeutique | Volume 17 | 1 | 2021-01-26 | p. 1-11 | 1769-7255 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-nephrologie-et-therapeutique-2021-1-page-1?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-nephrologie-et-therapeutique-2021-1-page-1?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux